Xenetic’s strategy as a Speciality Drug Developer has at its core the Company’s three patented drug delivery platforms that allow the creation of novel and next generation drug and vaccine candidates with applications over a broad range of therapeutic areas.

While proprietary drug development in the orphan drug sector will be a first priority, the Company will continue to seek out-licensing arrangements with leading Big Bio and Big Pharma partners for the development of novel or next generation therapeutics.

Xenetic has already established a clinical record for potential blockbuster candidates for the treatment of anaemia and diabetes; and, through its various development agreements in Russia, India and elsewhere (such as that established in 2006 with Baxter Healthcare) the Company believes that the dissemination, application and commercialisation of its technologies will be better facilitated by the outlicensing of multiple product candidates currently beyond its economic capacity to develop in-house.